%D9%86%D8%A8%D9%8A%D9%83%D8%B3%D9%8A%D9%85%D9%88%D9%84%D8%B3NabiximolsNabiximolsNabiximols%D9%86%D8%A7%D8%A8%DB%8C%DA%A9%D8%B3%DB%8C%D9%85%D9%88%D9%84%D8%B3NabiximolsNabiximols%E3%83%8A%E3%83%93%E3%82%AD%E3%82%B7%E3%83%A2%E3%83%AB%E3%82%B9SativexSativexSativex%D0%9D%D0%B0%D0%B1%D0%B8%D0%BA%D1%81%D0%B8%D0%BC%D0%BE%D0%BB%D1%81NabiksimolsNabiksimolsNabiximolsQ891968
about
sameAs
Sativex for Treatment of Chemotherapy Induced Neuropathic PainNeurophysiological Study of Sativex in Multiple Sclerosis (MS) SpasticityA Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced CancerSativex® for Relieving Persistent Pain in Patients With Advanced CancerLong Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related PainStudy to Assess Food Effect on Sativex BioavailabilitySativex Thorough QT/QTc StudyComparison of Safety, Tolerability and Pharmacokinetics of Medical Grade Cannabis (MGC) Orally Disintegrating Tablets With Buccal Sativex®, in Healthy Adult VolunteersSativex® for Relieving Persistent Pain in Participants With Advanced CancerEffects of Sativex(Registered Trademark) and Oral THC on Attention, Affect, Working Memory, Reversal Learning, Physiology and Brain ActivationAn Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple SclerosisAn Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis PatientsA Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple SclerosisA Study of Cannabis Based Medicine Extracts and Placebo in Patients With Pain Due to Spinal Cord InjuryA Study to Compare Sublingual Cannabis Based Medicine Extracts With Placebo to Treat Brachial Plexus Injury PainA Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological OriginA Study of the Long-term Safety of Sativex UseA Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple SclerosisA Study of Sativex® for Relief of Peripheral Neuropathic Pain Associated With Allodynia.A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.A Study of Sativex® for Pain Relief of Peripheral Neuropathic Pain, Associated With AllodyniaA Study of Sativex® for Pain Relief Due to Diabetic NeuropathyEvaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple SclerosisA Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple SclerosisStudy to Compare the Safety and Tolerability of Sativex® in Patients With Cancer Related PainA Study of Sativex® for Pain Relief in Patients With Advanced MalignancyFixed or Self-Titrated Dosages of Sativex on Cannabis UsersAn Observational Post-Marketing Safety Registry of Sativex®A Study to Assess the Pharmacokinetic (PK) Properties of Sativex® in Patients With Advanced CancerA Randomised, Open-label, Three-way Crossover Study to Assess the Pharmacokinetics and Safety of Single Doses of Four Sprays of Sativex® in a Range of Oral pH Environments in Healthy SubjectsExperimental Medicine in ADHD - CannabinoidsA Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma PatientsA Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent GlioblastomaA Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple SclerosisCombination of an Investigational Cannabinoid and Methadone for HIV-associated NeuropathyA Study to Determine the Maintenance of Effect After Long-term Treatment of Sativex® in Subjects With Neuropathic PainA Study to Compare the Safety and Tolerability of Sativex® in Patients With Neuropathic Pain.A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)Anesthetic Premedication With a Cannabis Extract (Cannapremed)A Study to Evaluate the Pharmacokinetics Of Sativex® in Subjects With Severe Renal Impairment or End Stage Renal Disease, Compared to Matched Subjects With Normal Renal Function.
P4844
Q61980506-BC3951CA-AB96-4594-85CE-6EDC874B3BBEQ63319848-1C0A7355-8B1C-4451-98B3-D76CD88E2379Q63321495-A70E3F9C-ECF8-441D-A64E-EAF50793A80EQ63335100-27EB4723-B1CB-4DED-B614-4F424DD1E1CBQ63335711-3407628B-5BBA-442B-8C2D-E76B160B5A5DQ63335870-4A6206C2-7566-44A5-8A8B-F6549856D26BQ63335979-8BB9FBE5-EC23-46F6-B46B-B46929CDC0C4Q63574664-2B978821-4250-4348-8A56-8A765FB746E4Q63817165-53A8189E-3106-4786-AFF3-3306791C97FAQ63834732-2404A2E3-17AE-4D34-8A48-3DDA3483180BQ63841315-18339890-500F-4938-94DE-4783086F8065Q63841322-394A9379-DA53-4AB0-ACE7-50000931649CQ63841334-AC1914D5-68DB-4B40-91B3-4011904625F5Q63842994-4E9EF308-65E5-4500-A8B6-267D1444254FQ63842997-B2CC74B5-BABA-46D9-8E4A-1FF117574544Q63843001-86DBD301-5026-429A-9A2B-6B6129787CFEQ63843011-782F2A66-4F58-411F-B782-1AE9D05D4562Q63843468-0D10CBA5-CC65-4C34-B416-F5BF5E8A065BQ64040554-0355262B-5CB0-4565-AFBB-6BD543308B3AQ64040600-9EDDF157-949A-4CA2-BE23-343F2CE42E94Q64040852-5CE3DE13-9D83-4DD9-B5D3-2C0F7FE4C0F2Q64040895-EEFF8758-1741-4BD3-9AE9-9294F4B6B2D1Q64042492-E2D6FBF8-BDAE-4458-9902-BD9F89BF5D99Q64046265-8845E1D6-99A2-4C86-AA1C-FF23C28A575CQ64046763-5E391644-6010-4F37-A0F2-DE122C3B3F4EQ64047019-C83322D8-7424-45B8-957C-248DCD84CDA0Q64071422-361942D0-836A-47E0-BB32-86EA39B94404Q64222477-06224DA0-B1EC-4B6B-B143-24897CBB6288Q64393434-28F95417-EAD8-4D8A-83A9-6DF8A35DD65AQ64606949-3EDD83F3-011F-45DC-8F7F-D7E0F2554D39Q64608712-75C895F6-0D97-472B-A17F-5D07B4EAE4EFQ64626110-749E157B-6E45-4740-A081-681D536F3A7FQ64626111-8328C23E-B768-4E59-8D2C-39E557F45F90Q64645354-26CA1243-66A8-4CDF-8C0C-5A85FE358B0DQ64717013-446F0A75-89E4-4DDE-BDBA-BB97853A2223Q64719068-73015855-6BDD-4D3B-846A-787B9A97E030Q64719170-C038FF56-B8BA-4ACA-8CC1-88DD3BF98779Q64719540-E6041BFA-2319-4FB2-B45D-FE25D4FBFECDQ65351400-590893EA-9509-4DD8-9F5A-F5CAB2D7E55FQ65353232-DD4CAA92-E7E1-4B09-A731-3DA8D99136C2
P4844
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Nabiksimols
@sh
Nabiksimols
@sr
Nabiximols
@de
Nabiximols
@en
Nabiximols
@nl
Nabiximols
@vi
Sativex
@es
Sativex
@it
Sativex
@nb
Sativex
@pl
type
label
Nabiksimols
@sh
Nabiksimols
@sr
Nabiximols
@de
Nabiximols
@en
Nabiximols
@nl
Nabiximols
@vi
Sativex
@es
Sativex
@it
Sativex
@nb
Sativex
@pl
altLabel
Sativex
@ru
Sativex®
@sv
Сативекс
@ru
نبيكسيمولات
@ar
サティベックス
@ja
prefLabel
Nabiksimols
@sh
Nabiksimols
@sr
Nabiximols
@de
Nabiximols
@en
Nabiximols
@nl
Nabiximols
@vi
Sativex
@es
Sativex
@it
Sativex
@nb
Sativex
@pl
P486
P6366
P646
P661
P662
P2017
CCCCCC1=CC(=C(C(=C1)O)C2C=C(CC ...... =C(CC[C@H]3C(O2)(C)C)C)C(=C1)O
P2067
P231
56575-23-6
P233
CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O.CCCCCC1=CC2=C(C3C=C(CCC3C(O2)(C)C)C)C(=C1)O
P234
1S/2C21H30O2/c1-5-6-7-8-15-12- ...... ,3-4H3/t16-,17-;17-,18?/m10/s1
P235
SSNHGLKFJISNTR-FWUPRJFYSA-N
P274
P2868
P3117
DTXSID40972015
P486
P6366
2780509889
P646
P652
K4H93P747O